153 related articles for article (PubMed ID: 31842358)
1. Less Cytotoxic Protoflavones as Antiviral Agents: Protoapigenone 1'-
Vágvölgyi M; Girst G; Kúsz N; Ötvös SB; Fülöp F; Hohmann J; Servais JY; Seguin-Devaux C; Chang FR; Chen MS; Chang LK; Hunyadi A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842358
[TBL] [Abstract][Full Text] [Related]
2. Direct semi-synthesis of the anticancer lead-drug protoapigenone from apigenin, and synthesis of further new cytotoxic protoflavone derivatives.
Hunyadi A; Chuang DW; Danko B; Chiang MY; Lee CL; Wang HC; Wu CC; Chang FR; Wu YC
PLoS One; 2011; 6(8):e23922. PubMed ID: 21912610
[TBL] [Abstract][Full Text] [Related]
3. Protoflavones in melanoma therapy: Prooxidant and pro-senescence effect of protoapigenone and its synthetic alkyl derivative in A375 cells.
Csekes E; Vágvölgyi M; Hunyadi A; Račková L
Life Sci; 2020 Nov; 260():118419. PubMed ID: 32931795
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Epstein-Barr virus lytic cycle by protoapigenone.
Tung CP; Chang FR; Wu YC; Chuang DW; Hunyadi A; Liu ST
J Gen Virol; 2011 Aug; 92(Pt 8):1760-1768. PubMed ID: 21490247
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxic activity of novel protoflavone analogs - selectivity towards a multidrug resistant cancer cell line.
Danko B; Martins A; Chuang DW; Wang HC; Amaral L; Molnár J; Chang FR; Wu YC; Hunyadi A
Anticancer Res; 2012 Jul; 32(7):2863-9. PubMed ID: 22753749
[TBL] [Abstract][Full Text] [Related]
6. First total synthesis of protoapigenone and its analogues as potent cytotoxic agents.
Lin AS; Nakagawa-Goto K; Chang FR; Yu D; Morris-Natschke SL; Wu CC; Chen SL; Wu YC; Lee KH
J Med Chem; 2007 Aug; 50(16):3921-7. PubMed ID: 17622129
[TBL] [Abstract][Full Text] [Related]
7. Protoapigenone derivatives: albumin binding properties and effects on HepG2 cells.
Poór M; Li Y; Kunsági-Máté S; Varga Z; Hunyadi A; Dankó B; Chang FR; Wu YC; Kőszegi T
J Photochem Photobiol B; 2013 Jul; 124():20-6. PubMed ID: 23648796
[TBL] [Abstract][Full Text] [Related]
8. A novel, broad-spectrum antitumor compound containing the 1-hydroxycyclohexa-2,5-dien-4-one group: the disclosure of a new antitumor pharmacophore in protoapigenone 1.
Yuan Q; Liu Z; Xiong C; Wu L; Wang J; Ruan J
Bioorg Med Chem Lett; 2011 Jun; 21(11):3427-30. PubMed ID: 21515048
[TBL] [Abstract][Full Text] [Related]
9. Protoapigenone, a natural derivative of apigenin, induces mitogen-activated protein kinase-dependent apoptosis in human breast cancer cells associated with induction of oxidative stress and inhibition of glutathione S-transferase π.
Chen WY; Hsieh YA; Tsai CI; Kang YF; Chang FR; Wu YC; Wu CC
Invest New Drugs; 2011 Dec; 29(6):1347-59. PubMed ID: 20686818
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR Study of Anticancer Protoflavone Derivatives: Investigation of Cytotoxicity and Interaction with ABCB1 and ABCG2 Multidrug Efflux Transporters.
Dankó B; Tóth S; Martins A; Vágvölgyi M; Kúsz N; Molnár J; Chang FR; Wu YC; Szakács G; Hunyadi A
ChemMedChem; 2017 Jun; 12(11):850-859. PubMed ID: 28436164
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Nontoxic Protoflavone Derivatives through Selective Continuous-Flow Hydrogenation of the Flavonoid B-Ring.
Ötvös SB; Vágvölgyi M; Girst G; Kuo CY; Wang HC; Fülöp F; Hunyadi A
Chempluschem; 2018 Feb; 83(2):72-76. PubMed ID: 31957309
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: structure-activity relationships.
Lin JC; Cherng JM; Hung MS; Baltina LA; Baltina L; Kondratenko R
Antiviral Res; 2008 Jul; 79(1):6-11. PubMed ID: 18423902
[TBL] [Abstract][Full Text] [Related]
13. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
14. Genipin as a novel chemical activator of EBV lytic cycle.
Son M; Lee M; Ryu E; Moon A; Jeong CS; Jung YW; Park GH; Sung GH; Cho H; Kang H
J Microbiol; 2015 Feb; 53(2):155-65. PubMed ID: 25626372
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
17. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
18. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
Huang L; Yang M; Yuan Y; Li X; Kuang E
Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
20. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
